Addressing Misunderstandings in Applying HBV Treatment Guidelines

Determining the level of fibrosis is key in evaluating patients for HBV treatment candidacy. How, when, and why should we incorporate fibrosis assessments into clinical practice? Here’s my take.

Paul Y. Kwo, MD Released: February 18, 2021

How I incorporate family history into HBV treatment and monitoring decisions in certain clinical gray zones.

Anna Christina L. dela Cruz, MD Released: April 15, 2021

Why I consider treatment for patients with immune-tolerant chronic HBV, and where I differ from current international guidance.

Ira M. Jacobson, MD Released: May 14, 2021

When managing pregnant patients with chronic HBV, the optimal timing for prophylaxis discontinuation postpartum remains unclear. Here’s my approach.

Joseph Ahn, MD, MS, MBA Released: July 13, 2021

In episode 2 of this ongoing series, listen to a conversation between Robert G. Gish, MD, FAASLD, and patient and advocate, Alan Wang, on approaches to destigmatize HBV infection and remove barriers to care.

Robert G. Gish, MD Released: April 12, 2021

In episode 3 of this ongoing series, listen to a conversation between Jordan J. Feld, MD, MPH, and Wendy, who is living with chronic hepatitis B, on incorporating shared decision-making to determine when to initiate treatment.

Jordan J. Feld, MD, MPH Released: May 11, 2021

In episode 5 of an ongoing series of sharing sessions between a physician and patient, Anna Christina L. dela Cruz, MD, and Rhonda, who is living with chronic hepatitis B, discuss what to do when the decision to start treatment is not clear because of borderline ALT test results and HBV DNA levels.

Anna Christina L. dela Cruz, MD Released: July 28, 2021

This concise MedicalMinute presentation reviews the natural history of HBV infection and interpreting serology, HBV DNA, and fibrosis assessments to determine treatment candidacy.

Paul Y. Kwo, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 16, 2021 Expired: No longer available for credit

Review AASLD guideline recommendations informing HBV pretreatment evaluation, including serology, HBV DNA, and fibrosis assessments to determine treatment candidacy.

Paul Y. Kwo, MD Released: February 16, 2021

This concise MedicalMinute presentation reviews the AASLD guidelines on monitoring and treatment for patients with HBV infection, including a brief discussion of HCC risk in various patient populations.

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 26, 2021 Expired: No longer available for credit

Review key data and AASLD guideline recommendations on HCC risk, considerations for treatment, and optimal HCC monitoring.

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Released: March 26, 2021

This concise MedicalMinute presentation reviews the AASLD recommendations on methods to assess liver fibrosis and inflammation and data and guidance on translating test results into management decisions.

Anna Christina L. dela Cruz, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: April 20, 2021 Expired: No longer available for credit

Review key data and AASLD guideline recommendations on methods to evaluate liver fibrosis and inflammation to guide management decisions for patients with HBV infection.

Anna Christina L. dela Cruz, MD Released: April 20, 2021

This concise MedicalMinute presentation reviews the AASLD recommendations for caring for pregnant women with chronic HBV infection, including considerations for monitoring, treatment indications, treatment options, and prophylaxis to prevent mother-to-child transmission.

Joseph Ahn, MD, MS, MBA Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: July 8, 2021 Expired: No longer available for credit

Review key data and AASLD guideline recommendations on managing HBV infection during pregnancy, including treatment indications, treatment options, and prophylaxis to prevent mother-to-child transmission.

Joseph Ahn, MD, MS, MBA Released: July 8, 2021

Patients with immune-tolerant hepatitis B often do not require treatment, but certain characteristics may change the treatment decision for an individual patient. Hear expert insights on when and why we treat certain immune-tolerant patients with HBV.

Norah Terrault, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 15, 2021 Expired: No longer available for credit